Voriconazole-micafungin combination therapy for acute lymphoblastic leukemia.
Okamoto
Takaaki
T
Department of Pediatrics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Koh
Katsuyoshi
K
Takita
Junko
J
Furuya
Ayaka
A
Kato
Motohiro
M
Ida
Kohmei
K
D000935:Antifungal Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D041022:Candida tropicalis; D002177:Candidiasis / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D054714:Echinocandins / Q000008:administration & dosage* / Q000009:adverse effects; D005500:Follow-Up Studies; D016469:Fungemia / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D055666:Lipopeptides / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D000077551:Micafungin; D009894:Opportunistic Infections / Q000188:drug therapy*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D055732:Pulmonary Aspergillosis / Q000188:drug therapy*; D011743:Pyrimidines / Q000008:administration & dosage* / Q000009:adverse effects; D014057:Tomography, X-Ray Computed; D014230:Triazoles / Q000008:administration & dosage* / Q000009:adverse effects; D065819:Voriconazole
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole; D000077551:Micafungin